Oncode Scientific

[pdf-embedder url="https://oncodesc.com/wp-content/uploads/2020/12/Risk-assessment-1_compressed.pdf"] [pdf-embedder url="https://oncodesc.com/wp-content/uploads/2020/12/Risk-assessment-2_compressed.pdf"]

Cancer Hereditary NGS Panel

PRODUCT DESCRIPTION

NGS panel specifically designed to target 31 germline genes known to be associated with hereditary cancer predisposition. This panel detects genetic variations in these genes, enabling the identification and assessment of potential inherited cancer risks in individuals.

Highlighted Genes:

Germline BRCA1&2, BARD1, PALB2, CHEK2, TP53, MLH1, MSH2, MSH6, PMS2, PTEN, STK11, EPCAM etc.

Alterations Detected:

SNVs, InDels, Large Genomic Rearrangements, Large Deletion/Duplications and CNVs.

FEATURES

  • Identifies genetic alterations in genes associated with over 40 hereditary cancer predispositions & syndromes.

  • Pre- and Post-test Genetic Counselling services for patients are available.

  • Provides a report with a personalized, evidence-based management plan.

CANCER HEREDITARY GENETIC TESTING OFFERS THE FOLLOWING BENEFITS:

  1. Assesing Cancer Risk:

    Determines an individual’s risk of developing cancer and enables appropriate screening and risk reduction options.

  2. Guiding Treatment:

    Identifies genetic mutations that may help tailor treatment plans and select the most effective interventions for individual patients.

  3. Identifying High-Risk Family Members:

    Helps identify relatives who may have an increased cancer risk, allowing for early intervention and preventive measures.

  4. Understanding Inheritance Patterns:

    Determines if faulty cancer-related genes have been inherited from parents, aiding in family planning and genetic counseling.